JSPR20250718C30
JSPR Jul 18 2025 30.00 Call (JSPR250718C00030000)
option OPRA

jasper therapeutics is a biotechnology company focused on enabling safer conditioning agents to allow for expanded use of curative therapy with stem cell transplants and gene therapies. jasper's lead compound, jsp191, is in clinical development as a conditioning antibody that clears hematopoietic stem cells from bone marrow in patients undergoing a stem cell transplant.